MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

225.46
+2.05
+0.92%
Closed 17:25 11/25 EST
OPEN
224.63
PREV CLOSE
223.41
HIGH
227.24
LOW
222.76
VOLUME
283.84K
TURNOVER
--
52 WEEK HIGH
240.58
52 WEEK LOW
66.01
MARKET CAP
11.34B
P/E (TTM)
-29.2714
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Small cap stocks are at a record and these hedge fund favorites in the group are doing even better
RBC found 20 small-cap names most loved by hedge funds, and they have outperformed the Russell 2000 by 61.5% on average so far in 2020.
CNBC.com · 2d ago
Qorvo® to Present at Wells Fargo TMT Virtual Summit
GREENSBORO, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Qorvo® (Nasdaq: QRVO), a leading provider of innovative RF solutions that connect the world, today announced that Company executives are scheduled to present at the Wells Fargo Tech, Media & Telecom (“TMT”) Virtual Summit on Tuesday, December 1, 2020 at 10:00 a.m. ET. A live webcast of the virtual event will be available on the Company's web site at the following URL: http://www.qorvo.com (under "Investors").About Qorvo Qorvo (Nasdaq: QRVO) makes a better world possible by providing innovative Radio Frequency (RF) solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers’ most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including advanced wireless devices, wired and wireless networks and defense radar and communications. We also leverage unique competitive strengths to advance 5G networks, cloud computing, the Internet of Things, and other emerging applications that expand the global framework interconnecting people, places and things. Visit www.qorvo.com to learn how Qorvo connects the world.Qorvo is a registered trademark of Qorvo, Inc. in the U.S. and in other countries. All other trademarks are the property of their respective owners.This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions, and are not historical facts and typically are identified by use of terms such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements included herein represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those expressed or implied by forward-looking statements. We do not intend to update any of these forward-looking statements or publicly announce the results of any revisions to these forward-looking statements, other than as is required under U.S. federal securities laws. Our business is subject to numerous risks and uncertainties, including those relating to fluctuations in our operating results; our substantial dependence on developing new products and achieving design wins; our dependence on a few large customers for a substantial portion of our revenue; a loss of revenue if contracts with the United States government or defense and aerospace contractors are canceled or delayed or if defense spending is reduced; the COVID-19 pandemic, which has and will likely continue to negatively impact the global economy and disrupt normal business activities, and which may have an adverse effect on our results of operations; our dependence on third parties; risks related to sales through distributors; risks associated with the operation of our manufacturing facilities; business disruptions; poor manufacturing yields; increased inventory risks and costs due to timing of customer forecasts; our inability to effectively manage or maintain evolving relationships with platform providers; risks from international sales and operations; economic regulation in China; changes in government trade policies, including imposition of tariffs and export restrictions; our ability to implement innovative technologies; underutilization of manufacturing facilities as a result of industry overcapacity; we may not be able to borrow funds under our credit facility or secure future financing; we may not be able to generate sufficient cash to service all of our debt; restrictions imposed by the agreements governing our debt; volatility in the price of our common stock; damage to our reputation or brand; fluctuations in the amount and frequency of our stock repurchases; our recent and future acquisitions and other strategic investments could fail to achieve financial or strategic objectives; our ability to attract, retain and motivate key employees; our reliance on our intellectual property portfolio; claims of infringement of third-party intellectual property rights; security breaches and other similar disruptions compromising our information; theft, loss or misuse of personal data by or about our employees, customers or third parties; warranty claims, product recalls and product liability; and risks associated with environmental, health and safety regulations and climate change. Many of the foregoing risks and uncertainties are, and will continue to be, exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. These and other risks and uncertainties, which are described in more detail in Qorvo’s most recent Annual Report on Form 10-K and in other reports and statements filed with the Securities and Exchange Commission, could cause actual results and developments to be materially different from those expressed or implied by any of these forward-looking statements. CONTACT: At Qorvo® Doug DeLieto VP, Investor Relations 1- 336-678-7968
GlobeNewswire · 2d ago
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1st at 8:20 a.m. PT/11:20 a.m. ET. Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.
PR Newswire · 3d ago
Stock Market Rally Rotation Over As Coronavirus Cases Soar? Qualcomm Near Buy Point; Apple, Microsoft, Amazon Look Tired
Investor's Business Daily · 5d ago
Stock Market Rally Holds Tight; Qualcomm, Qorvo Near Buy Points; Apple, Microsoft, Amazon Look Tired
Investor's Business Daily · 5d ago
Qorvo, IBD Stock Of The Day, Is Forming This Bullish Stock Chart Pattern
Qorvo stock is the IBD Stock Of The Day as the wireless chipmaker benefits from the launch of Apple's iPhone 12 and other 5G smartphones.
Investor's Business Daily · 6d ago
Qorvo CEO Bob Bruggeworth Elected Chair of Semiconductor Industry Association
The Semiconductor Industry Association (SIA) Board of Directors today elected Bob Bruggeworth, President, CEO, and Director of Qorvo (NASDAQ: QRVO), as its 2021 Chair and Steve Mollenkopf, CEO and Director of Qualcomm Incorporated (NASDAQ: QCOM), as its 2021 Vice Chair. SIA represents 98 percent of the U.S. semiconductor industry by revenue and nearly two-thirds of non-U.S. chip firms.
PR Newswire · 11/19 19:26
What Can We Learn About Qorvo's (NASDAQ:QRVO) CEO Compensation?
Bob Bruggeworth has been the CEO of Qorvo, Inc. (NASDAQ:QRVO) since 2013, and this article will examine the...
Simply Wall St. · 11/16 14:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRTX. Analyze the recent business situations of Mirati through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRTX stock price target is 235.57 with a high estimate of 300.00 and a low estimate of 176.00.
EPS
Institutional Holdings
Institutions: 312
Institutional Holdings: 57.75M
% Owned: 114.86%
Shares Outstanding: 50.28M
TypeInstitutionsShares
Increased
65
3.03M
New
69
405.25K
Decreased
80
3.73M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Director
Faheem Hasnain
Chairman/Director
faheem Hasnain
President/Chief Executive Officer/Director
Charles Baum
Chief Operating Officer/Executive Vice President
Daniel Faga
Executive Vice President/Chief Scientific Officer
James Christensen
Executive Vice President
Benjamin Hickey
Senior Vice President/Chief Accounting Officer
Vickie Reed
Other
Joseph Leveque
Independent Director
Bruce Carter
Vice President/Director of Human Resources
Jenny Gizzi
Independent Director
Julie Cherrington
Independent Director
Aaron Davis
Independent Director
Henry Fuchs
Independent Director
Michael Grey
Independent Director
Craig Johnson
Independent Director
Maya Martinez-Davis
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRTX
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.